Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GCGR | P47871 | 5/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 6/20 | 0.45 |
| ▸ | NPC1 | O15118 | 3/20 | 0.45 |
| ▸ | RAB9A | P51151 | 3/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | SAE1 | Q9UBE0 | 1/20 | 0.45 |
| ▸ | UBA2 | Q9UBT2 | 1/20 | 0.45 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4355054 | 0.85 | GCGR (0.47) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4045250 | 0.84 | GCGR (0.71) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4038180 | 0.80 | GCGR (0.60) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4355044 | 0.78 | MTNR1A (0.40) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4037920 | 0.78 | GCGR (1.00) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4355057 | 0.77 | GCGR (0.40) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL2648406 | 0.77 | GCGR (0.70) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4355052 | 0.77 | MTNR1B (0.44) | GCGRMAPTNPSR1SAE1UBA2 | |
| SCHEMBL6316697 | 0.76 | GCGR (0.61) | GCGRALDH1A1NPC1RAB9AL3MBTL1 | |
| SCHEMBL4039316 | 0.76 | GCGR (0.59) | GCGRALDH1A1NPC1RAB9AL3MBTL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1620437-B1 | 5,7-DIAMINOPYRAZOLO¬4,3-D PYRIMIDINES USEFUL IN THE TRAETMENT OF HYPERTENSION | PFIZER LTD (GB) | 2009-06-17 | — | — | EP | claimed |
| EP-1549655-B1 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | claimed |
| EP-1549655-A4 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2006-05-31 | — | — | EP | claimed |
| EP-1549655-A2 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | Merck & Co., Inc. (US) | 2005-07-06 | — | — | EP | claimed |
| WO-2004024065-A2 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO., INC. (US) | 2004-03-25 | — | — | WO | claimed |
| EP-1284977-B1 | THIENODIBENZOAZULENE COMPOUNDS AS TUMOR NECROSIS FACTOR INHIBITORS | GLAXOSMITHKLINE ZAGREB (HR) | 2009-06-24 | — | — | EP | disclosed |
| EP-1549655-B1 | SUBSTITUTED BICYCLIC THIOPHENE DERIVATIVES, COMPOSTIONS CONTAINING SUCH COMPOUNDS AND METHODS OF USE | MERCK & CO INC (US) | 2009-01-21 | — | — | EP | disclosed |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA D.D. (HR) | 2005-08-04 | — | — | US | disclosed |
| US-6897211-B2 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA-ISTRAZIVACKI INSTITUT D.O.O. (HR) | 2005-05-24 | — | — | US | disclosed |
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | PLIVA FARMACEUTSKA INDUSTRIJA, DIONICKO DRUSTVO | 2003-08-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030153750-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | GCGR 3256/4885ALDH1A1 48/4885NPC1 3582/4885 |
| US-20050171091-A1 | Thienodibenzoazulene compounds as tumor necrosis factor inhibitors | TNF, IL1B, IL1A | GCGR 3270/4885ALDH1A1 58/4885NPC1 3464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.